Prismatic Correction for Improving Near Visual Acuity in Patients With Maculopathy

• Sponsor: Al-Shifa Trust Eye Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT05747417
• Collaborator: (none)
• Enrollment: 100
• Location: 1
• Arms: 2
• Actual Duration (Months): 7
• Patients Per Site Per Month: 14.3

Study Details

Study Description

Brief Summary

patients with maculopathy reported in low vision clinic are tested for prismatic glasses for near vision. The pre and post visual acuity was recorded.

Condition or Disease	Intervention/Treatment	Phase
Visual Acuity	Other: prismatic glasses	N/A

Detailed Description

Diagnosed patient of maculopathy who was visited in low vision clinic are divided in two groups , one is control group (prescribed simple near vision glasses) and other is interventional group(prescribed prismatic glasses). Both groups were follow up after one month to check the improvement in near visual acuity

Study Design

• Study Type: Interventional
• Actual Enrollment: 100 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Investigator)
• Primary Purpose: Supportive Care
• Official Title: Prismatic Correction for Improving Near Visual Acuity in Patients With Maculopathy
• Actual Study Start Date: Jun 1, 2022
• Actual Primary Completion Date: Dec 31, 2022
• Actual Study Completion Date: Dec 31, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: prism glasses prisms glasses are advised with ranging of 4prism diopters to 10 prism diopters	Other: prismatic glasses; prism glasses ranging from 4-10 prism diopters
No Intervention: presbyopic glasses simple presbyopia glasses according to age are advised

Outcome Measures

Primary Outcome Measures

1. Prismatic Correction for Improving Near Visual Acuity in Patients with Maculopathy [7 -8 months]

   A Per forma/questionnaire is used to document Near visual Acuity with the help of light house Chart to see improvement in visual acuity

Eligibility Criteria

Criteria

• Ages Eligible for Study: 40 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Diagnosed patients of maculopathy refer to low vision clinic

2. Patients with both genders

3. VA from LogMAR 1.0 to LogMAR 0.3

Exclusion Criteria:

1. Maculopathy patients with other ocular disease

2. VA worsen the LogMAR 1.0

3. Patients with mental illness and other physical lmitations

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Al Shifa Trust Eye Hospital Rawalpindi	Rawalpindi	Punjab	Pakistan

Sponsors and Collaborators

• Al-Shifa Trust Eye Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Mehreen Tanveer, Manager Light House, Al-Shifa Trust Eye Hospital
• ClinicalTrials.gov Identifier: NCT05747417
• Other Study ID Numbers: AlShifaTrust Eye
• First Posted: Feb 28, 2023
• Last Update Posted: Feb 28, 2023
• Last Verified: Feb 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Macular Degeneration

Study Results

No Results Posted as of Feb 28, 2023